SHANGHAI and PHILADELPHIA, June 1, 2020 — WuXi AppTec, a leading global pharmaceutical and medical device open-access capability and technology platform company, announced today the appointment of Dr. David Chang as Chief Executive Officer of WuXi Advanced...
World-class platform will enable biotechnology companies and researchers to accelerate the development, manufacturing and release of cell and gene therapies for patients May 18, 2020 – Philadelphia, PA – WuXi Advanced Therapies, a leading global Contract...
New AAV Vector Suspension platform complements integrated capabilities – enabling cell and gene therapies to be developed, manufactured, and released faster and with greater predictability globally. January 13, 2020 – Philadelphia, PA – WuXi Advanced...
SHANGHAI and SEOUL, South Korea, Nov. 28, 2019 /PRNewswire/ — WuXi ATU Co., Ltd., (WuXi ATU) – a subsidiary of WuXi AppTec, and GeneMedicine – a South Korea-based gene therapy biotechnology company, have formed a strategic partnership for the...
San Francisco and Philadelphia – November 6, 2019 — Vineti, a leading provider of a digital platform of record for personalized therapies, and WuXi AppTec Advanced Therapies, a Contract Development and Manufacturing Organization (CDMO) have entered into a...
Partnership combines global CDMO services with industry leading cellular orchestration platform Cardiff, UK & Philadelphia, PA, October 1, 2019 – TrakCel, the software developer for cell and gene therapy supply chain tracking and orchestration systems and WuXi...
